One Good, One Bad News For Bristol Myers Squibb ' s Marketed Drugs: Details

Thursday, Bristol Myers Squibb & Co BMY announced an update following the initial analysis of results from the first of two induction studies in the Phase 3 YELLOWSTONE trial program of Zeposia (ozanimod) in adult patients with moderate to severe active Crohn’s disease. The study did not meet its…#zeposia #ozanimod #crohn #yellowstone #bristolmyerssquibb #nsclc #krasg12c #krazati #orr #fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news